Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06171750
Other study ID # ANK-101-001
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date January 19, 2024
Est. completion date January 2026

Study information

Verified date May 2024
Source Ankyra Therapeutics, Inc
Contact Gail Iodice, BSN, RN
Phone 347-882-1147
Email giodice@ankyratx.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase 1, multicenter, open-label dose escalation study to determine the safety and tolerability of intratumoral (IT) injection of ANK-101 in participants with advanced solid tumors who have progressed during or after receiving standard of care (SOC) therapy or who will not benefit from such therapy. The study will be conducted in two parts; Part 1 will enroll participants with superficial lesions and Part 2 will enroll participants with visceral lesions.


Description:

This Phase 1 first-in-human (FIH) study will: 1) evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic effects and preliminary clinical activity of ANK-101 administered as an intratumoral (IT) injection in participants with superficial or visceral lesions; and 2) determine the recommended dose for expansion (RDE) of ANK-101. For both parts, the study design consists of six sequential dose-escalation cohorts and an expansion cohort at the RDE. Part 1 will enroll participants with advanced solid tumors, with cutaneous, subcutaneous or nodal disease (accessible by clinical palpation or ultrasound guidance). Part 2 will start once the DLT period of dose level 1 in Part 1 is completed and dose level 2 is opened. Part 2 will enroll participants with visceral disease (accessible by interventional radiology or endoscopic techniques). Participants in Part 2 may also have superficial lesions that can be injected if in the Investigator's opinion this is clinically indicated. Ten participants will be dosed in a Part 1 dose expansion cohort at the RDE, and in Part 2, the dose expansion cohort at the RDE will include 10 participants with non-small cell lung cancer (NSCLC).


Recruitment information / eligibility

Status Recruiting
Enrollment 92
Est. completion date January 2026
Est. primary completion date July 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - = 18 years of age on day of signing informed consent - histologically or cytologically confirmed diagnosis of cutaneous, subcutaneous, soft tissue, or nodal advanced solid tumor malignancy; metastatic disease eligible - measurable disease per RECIST v1.1 - Note: Must have at least 1 tumor lesion with longest dimension of = 10 mm (= 15 mm for the short axis for malignant lymph node lesions) that - For Part 1 only: can be easily palpated or detected by ultrasound to facilitate IT injection of ANK-101 (i.e., tumor in skin, muscle, subcutaneous tissue, or accessible lymph node) or; - For Part 2 only: can be accessed by interventional radiologic or endoscopic procedures for injection (e.g., ultrasound or computed tomography [CT] guided). - For Part 2 Dose Expansion Cohort only: Histologically confirmed Stage III or Stage IV NSCLC - documented disease progression, be refractory to, or intolerant of existing SOC therapy(ies) known to provide clinical benefit (including surgical cure) or not be eligible for SOC therapy(ies) - ECOG performance status 0-1 - life expectancy > 12 weeks - adequate bone marrow, hepatic and renal function - baseline electrocardiogram (EKG) without evidence of acute ischemia or prolonged QTc interval > 460 msec - Human immunodeficiency virus (HIV) infected participants must be on anti-retroviral therapy (ART) and have well-controlled HIV infection/disease - last dose of previous anticancer therapy (including investigational agents) = 28 days, radiotherapy = 14 days (targeted palliative radiotherapy is allowed for lesions not planned for injections), or surgical intervention = 21 days prior to the start of treatment - resolution of all prior anticancer therapy toxicities (except for alopecia or vitiligo) to = Grade 1 (as per NCI CTCAE Version 5.0) - willing to provide pre- and post-treatment tumor biopsy samples if medically feasible - participant is capable of understanding and complying with protocol requirements Exclusion Criteria: - injectable tumors impinging upon major airways or blood vessels - prior treatment with recombinant interleukin-12 (IL-12) - have received systemic therapy with immunosuppressive agents = 28 days before the start of treatment - have received live vaccines within 28 days prior to the start of ANK-101 treatment - have primary or acquired immunodeficient states (e.g., leukemia, lymphoma) - a woman of childbearing potential (WOCBP) who has a positive serum pregnancy test (within 72 hours) prior to the start of treatment or female participant who is breastfeeding - prior organ transplantation - known history of hepatitis B virus, known active hepatitis C virus, or a positive serological test at screening within 28 days prior to the start of treatment - HIV-infected participants with a history of Kaposi sarcoma and/or Multicentric Castleman Disease - active autoimmune disease or medical conditions requiring chronic steroid (i.e., = 20 mg/day prednisone or equivalent) or other immunosuppressive therapy within 28 days prior to the start of treatment - known active central nervous system (CNS) metastases - congestive heart failure (> New York Heart Association Class II), active coronary artery disease, unevaluated new onset angina within 3 months or unstable angina (angina symptoms at rest), or clinically significant cardiac arrhythmias - uncontrolled bleeding disorders within 4 weeks prior to the start of treatment or known bleeding diathesis - Note: Part 2 only: Participants with active bleeding diathesis or requirement for therapeutic anticoagulation that cannot be interrupted or altered for procedures - history of hypersensitivity to compounds of similar biological composition to IL-12, aluminum hydroxide, or drugs formulated with polysorbate-20 - other systemic conditions or organ abnormalities that, in the opinion of the Investigator, may interfere with the conduct and/or interpretation of the current study - any acute or chronic psychiatric problems or substance abuse disorder that, in the opinion of the Investigator, make the participant unsuitable for participation

Study Design


Intervention

Drug:
ANK-101
IT administration of ANK-101 once every 3 weeks for up to 12 weeks (4 doses); if there is no disease progression, decrease in clinical performance status or unacceptable toxicity, participants may receive 4 additional doses of ANK-101.

Locations

Country Name City State
Canada Princess Margaret Cancer Centre Toronto Ontario
United States Massachusetts General Hospital Boston Massachusetts
United States Hillman Cancer Center Pittsburgh Pennsylvania
United States Providence Cancer Institute Portland Oregon

Sponsors (1)

Lead Sponsor Collaborator
Ankyra Therapeutics, Inc

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence and characteristics of DLTs and TEAEs Number and percentage of participants reporting each DLT or TEAE. From Day 1 to 90 days after last injection of ANK-101
Primary RDE of ANK-101 Defined based on the rate of DLTs and TEAEs Approximately 12 months
Secondary PK: Cmax of IL-12-ABP PK of IL-12-ABP as assessed by maximum plasma concentration (Cmax) Up to 2 years
Secondary PK: AUC of IL-12-ABP PK of IL-12-ABP as assessed by area under the time-concentration curve (AUC) Up to 2 years
Secondary PK: t ½ of IL-12-ABP PK of IL-12-ABP as assessed by terminal half-life (t ½) Up to 2 years
Secondary PK: CL/F of IL-12-ABP PK of IL-12-ABP as assessed by apparent clearance (CL/F) Up to 2 years
Secondary PK: Vss/F of IL-12-ABP PK of IL-12-ABP as assessed by apparent volume of distribution at steady state (Vss/F) Up to 2 years
Secondary Levels of ADA in serum Number and percentage of participants with serum levels of anti drug antibodies (ADA) after treatment Up to 2 years
Secondary ORR by RECIST v1.1 Number of participants with a best overall RECIST response (BOR) of CR or PR based on RECIST v1.1 Up to 2 years
Secondary DCR by RECIST v1.1 Number of participants with SD, CR and PR. Up to 2 years
Secondary DOR by RECIST v1.1 Time from when the criteria for RECIST v1.1 CR or PR (whichever is recorded first) was first met until the date when PD is documented Up to 2 years
Secondary PFS by RECIST v1.1 Time from C1D1 to PD or death from any cause UP to 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT05580991 - Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors Phase 1
Recruiting NCT05691608 - MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2 N/A
Active, not recruiting NCT02846038 - Understanding Communication in Healthcare to Achieve Trust (U-CHAT)
Recruiting NCT05159388 - A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors Phase 1/Phase 2
Completed NCT03181854 - Randomized Controlled Trial of Integrated Early Palliative Care N/A
Recruiting NCT05981703 - A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors Phase 1
Recruiting NCT06014502 - Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors Phase 1
Recruiting NCT04107311 - Prospective Analysis of Intestinal Microbiome and Autoimmune Panels as Predictors of Toxicity in ImmunOncology Patients
Active, not recruiting NCT04078152 - Durvalumab Long-Term Safety and Efficacy Study Phase 4
Completed NCT02250157 - A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies Phase 1
Recruiting NCT05566574 - A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer Phase 1/Phase 2
Recruiting NCT03943004 - Trial of DFP-14927 in Advanced Solid Tumors Phase 1
Recruiting NCT06036836 - Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) Phase 2
Recruiting NCT05798546 - Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02) Phase 1
Recruiting NCT05525858 - KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT00479128 - Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors Phase 1
Recruiting NCT04143789 - Evaluation of AP-002 in Patients With Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT04550663 - NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors Phase 1
Completed NCT03980041 - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Phase 2